Lenox Wealth Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Lenox Wealth Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-500	Closed	-$2K	–	1035
2021 Q4	$2K	Buy	+500	New	+$2.37K	﹤0.01%	777

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Fortress Investment Group New York $531M AUM 12.95% 1-Year Est. Return

Lenox Wealth Advisors's PRTK Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2022, closing a stake of 500 shares — an estimated $2K sold.

Lenox Wealth Advisors first reported a position in PRTK in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 100 funds tracked by Wall St. Rank hold PRTK as of Q1 2022.

Lenox Wealth Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Lenox Wealth Advisors sold 500 Paratek Pharmaceuticals, Inc. shares in Q1 2022, an estimated $2K.
Lenox Wealth Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
Lenox Wealth Advisors's Paratek Pharmaceuticals, Inc. position peaked at $2K in Q4 2021.
100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.